Previous 10 | Next 10 |
Clinical trial achieved all three primary objectives and subjects completed 16-week treatment with no significant safety issues Results indicate that DFD-29 can be safely used for up to 16 weeks with no significant risk of microbiota suppression or development of resistance Topl...
2023-05-23 10:08:04 ET Gainers: CohBar ( CWBR ) +157% . Ocean Biomedical ( OCEA ) +79% . Shuttle Pharmaceuticals ( SHPH ) +46% . Icosavax ( ICVX ) +31% . Recursion Pharmaceuticals ( RXRX ) +20% . Losers: NantHealth ( ...
2023-05-22 18:50:25 ET Journey Medical Corp (DERM) Q1 2023 Earnings Conference Call May 22, 2023 04:30 PM ET Company Participants Matt Blazei - CORE IR Claude Maraoui - Founder, President and CEO Joseph Benesch - Interim CFO Conference Call Participants ...
2023-05-22 16:52:28 ET Journey Medical press release ( NASDAQ: DERM ): Q1 Non-GAAP EPS of -$0.30. Revenue of $12.2M (-47.6% Y/Y) misses by $3.98M . At March 31, 2023, the Company had $26.1 million in cash and cash equivalents and restricted cash as compared to $32....
Achieved “Last Patient Out” milestone in Phase 3 clinical program evaluating DFD-29 in May 2023 Topline data are expected in June 2023 for Phase 3 clinical program evaluating DFD-29 Company to hold conference call on May 22, 2023, at 4:30 p.m. ET SCOTTSDALE, Ar...
SCOTTSDALE, Ariz., May 19, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treat...
2023-05-19 12:49:26 ET Gainers: Mallinckrodt ( MNK ) +251% . Biocept ( BIOC ) +47% . WISeKey International Holding ( WKEY ) +41% . Aemetis ( AMTX ) +33% . Crescera Capital Acquisition ( CREC ) +32% . Stereotaxis ( STXS ) ...
Fortress is advancing several late-stage clinical assets with two NDA submissions anticipated in second half of 2023 PDUFA goal date of January 3, 2024 set by FDA for cosibelimab to treat metastatic or locally advanced cutaneous squamous cell carcinoma MIAMI, May 15, 2023 (G...
2023-05-12 14:25:40 ET Journey Medical press release ( NASDAQ: DERM ): FY Non-GAAP EPS of -$0.42. Revenue of $73.7M beats by $1.09M . For further details see: Journey Medical Non-GAAP EPS of -$0.42, revenue of $73.7M beats by $1.09M
SCOTTSDALE, Ariz., May 11, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditio...
News, Short Squeeze, Breakout and More Instantly...
Journey Medical Corporation Company Name:
DERM Stock Symbol:
NASDAQ Market:
Journey Medical Corporation Website:
SCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescriptio...
Journey Medical Corporation (NASDAQ: DERM) is the focus of IBN's latest stock spotlight. The company's shares have moved -1.78% on the day to $5.51. Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological condi...
2024-07-07 18:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...